Default company panoramic image
Logo

SignalChem Lifesciences Corporation

SignalChem Lifesciences Corporation discovers and develops targeted therapies to treat cancer, IBD, RA, Parkinson, and Alzheimer's disease.

  • Stage Concept Only
  • Industry Biotechnology
  • Location Richmond, BC, Canada
  • Currency CAD
  • Website signalchemcorp.com

Company Summary

SignalChem Lifesciences Corporation (SLC) discovers and develops innovative novel small molecule targeted therapies for the treatment of cancer, inflammation/autoimmune and central nervous system diseases with unmet medical need. SLC addresses the growing market demand within and upon the pharmaceutical drug development industry for targeted therapies. SLC's products enable selection of the right drug for the right disease in the right patient.

Team

  • Default avatar
    Madhu Singh
    Director Regulatory and Clinical

    Dr. Singh is a senior regulatory professional with demonstrated experience in managing multidisciplinary drug development projects spanning preclinical, clinical and regulatory phases. Dr. Singh provides SLC with expertise in intensive regulatory intelligence, developing and implementing regulatory and clinical strategies, interaction with regulatory authorities, building and leading high-quality regulatory submissions and clinical documents.

  • Default avatar
    Zahir Popat
    Chairman and Chief Executive Officer

    Zahir Popat is an accomplished business professional with expertise constructing and managing successful lifesciences corporate alliances, and business relationships on 5 continents for over 30 years. Mr. Popat brings the expertise to structure and manage SLC to attain a global presence through the power of strategic partnerships and a network of global alliances that complement SLC’s in-house and international drug development capabilities.

  • Default avatar
    Jasbinder Sanghera
    President and Chief Scientific Officer

    Dr. Sanghera is a serial entrepreneur with 22 years of experience in drug discovery, protein kinase drug targets, signal transduction and cancer research. Dr. Sanghera has led teams that advanced three small molecule candidates from discovery into human clinical trials. His vision and goal for SLC is to target kinase cell signaling enzymes to create innovative targeted drug products for the treatment of the right disease in the right patient.

  • Default avatar
    Jun Yan
    Director Biology

    Mr. Yan is an expert in drug target discovery and validation, signal transduction, and cancer biology. He is a co-founder of SignalChem Pharmaceuticals Inc. and MetaSignal Therapeutics Inc. Jun Yan brings to SLC kinase biology expertise to produce and exploit novel protein kinases and cell signaling pathways as drug targets through the production of signal transduction proteins and design of optimal assay systems.

  • Default avatar
    Zhaihui Zhang
    Director Medicinal Chemistry

    Dr. Zhang made major contributions to advancing three small molecules from discovery stage to clinical trial stage. Dr. Zhang has also managed several programs that have been successfully acquired by or partnered with top tier multinational pharmaceutical companies and biotech companies as the Director or Associate Director of Medicinal Chemistry for Xenon Pharmaceuticals, Active Pass, and Kinetek Pharmaceuticals. He is an inventor on 50 patents

  • Default avatar
    Shoukat Dedhar
    Director Cancer Biology

    Dr. Dedhar is a world expert in cancer biology and cell adhesion mechanisms and signal transduction with expertise in in vivo models of invasion and metastasis. With more than 30 years of experience in cancer research, Dr. Dedhar has authored more than 170 publications in the cancer field and holds a number of patents. He is an inventor of the inhibitors of the enzyme target, CAIX, used in SLC’s hypoxia anticancer drug development program.

  • Default avatar
    Claudiu Supuran
    Director Drug Design

    Dr. Supuran is a world renowned medicinal chemist and a world expert on the chemistry of the hypoxia CAIX anticancer drug program inhibitors and activators. Dr. Supuran is co-author on more than 670 scientific publications and patents. He is a founder of SLC and he currently holds the position of Professor, Faculty of Pharmacy, Department of Chemistry, University of Florence.

  • Default avatar
    Kevin McDuffie
    Director Business Development

    Mr. McDuffie is an accomplished business professional with more than 25 years of business development, technology licensing, plus sales and marketing experience in the biotechnology, life science, and biomedical device markets. Kevin McDuffie brings to SLC expertise in structuring, implementing, and managing multiple partnerships, alliances, and technology licenses for drug development.